Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Hannah Petrek"'
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 13, Iss 8, Pp 3577-3578 (2023)
Externí odkaz:
https://doaj.org/article/ca5b224f44af4af3936dccb5197e7df3
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 11, Iss 12, Pp 3950-3965 (2021)
With the understanding of microRNA (miRNA or miR) functions in tumor initiation, progression, and metastasis, efforts are underway to develop new miRNA-based therapies. Very recently, we demonstrated effectiveness of a novel humanized bioengineered m
Externí odkaz:
https://doaj.org/article/c040d66051c9492c9abd9c8aaebf44d2
Autor:
Hannah Petrek, Ai‐Ming Yu
Publikováno v:
Pharmacology Research & Perspectives, Vol 7, Iss 6, Pp n/a-n/a (2019)
Abstract Lung cancer remains the most lethal cancer among men and women in the United States and worldwide. The majority of lung cancer cases are classified as non‐small cell lung cancer (NSCLC). Developing new therapeutics on the basis of better u
Externí odkaz:
https://doaj.org/article/e4a07a384a3d498ba88925d0652d4682
Publikováno v:
Acta Pharmaceutica Sinica. B
Acta Pharmaceutica Sinica B, Vol 11, Iss 12, Pp 3950-3965 (2021)
Acta Pharmaceutica Sinica B, Vol 11, Iss 12, Pp 3950-3965 (2021)
With the understanding of microRNA (miRNA or miR) functions in tumor initiation, progression, and metastasis, efforts are underway to develop new miRNA-based therapies. Very recently, we demonstrated effectiveness of a novel humanized bioengineered m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f2c94a550b226b027d4279bbc51b77d
http://europepmc.org/articles/PMC8727917
http://europepmc.org/articles/PMC8727917
Publikováno v:
Applied microbiology and biotechnology, vol 103, iss 15
Noncoding RNAs (ncRNAs), including microRNAs (miRNAs), small interfering RNAs (siRNAs), and long noncoding RNAs (lncRNAs), regulate target gene expression and can be used as tools for understanding biological processes and identifying new therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cf34a148efb36074959f96da33b088a
https://doi.org/10.1007/s00253-019-09934-5
https://doi.org/10.1007/s00253-019-09934-5
Publikováno v:
The FASEB Journal. 35
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3938d2661be263844caf031fe18ea142
https://doi.org/10.1096/fasebj.2021.35.s1.02586
https://doi.org/10.1096/fasebj.2021.35.s1.02586
Publikováno v:
Biochem Pharmacol
Lung cancer remains the leading cause of cancer deaths worldwide and accounts for more than 22% of all cancer-related deaths in the US. Developing new therapies is essential to combat against deadly lung cancer, especially the most common type, non-s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::325911278ba110b34e7bc421cda1a105
https://europepmc.org/articles/PMC8187260/
https://europepmc.org/articles/PMC8187260/
Autor:
Aiming Yu, Hannah Petrek
Publikováno v:
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives, Vol 7, Iss 6, Pp n/a-n/a (2019)
Pharmacology Research & Perspectives, Vol 7, Iss 6, Pp n/a-n/a (2019)
Lung cancer remains the most lethal cancer among men and women in the United States and worldwide. The majority of lung cancer cases are classified as non‐small cell lung cancer (NSCLC). Developing new therapeutics on the basis of better understand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9340014d3f659f963a37022756c1f79e
https://doi.org/10.1002/prp2.528
https://doi.org/10.1002/prp2.528
Publikováno v:
The FASEB Journal. 32
Lung cancer is the second most common cancer among both men and women in the United States. The majority of lung cancer cases are classified as non-small cell lung cancer (NSCLC). Current NSCLC tre...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6119705044cdcbe1dd0f7cb920c0ae7e
https://doi.org/10.1096/fasebj.2018.32.1_supplement.565.1
https://doi.org/10.1096/fasebj.2018.32.1_supplement.565.1